Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences
Argenx SE (ARGX) agreed to buy Forte Biosciences (FBRX) for about $2.2 billion in cash, offering $77 per share, a ~40% premium to Forte’s prior close. The deal includes Forte’s FB102 anti-CD122 antibody and is expected to close in Q3 2026, pending approvals. Both boards approved.
How this was made
The 30-second read
Why it matters
The acquisition adds an experimental first-in-class anti-CD122 antibody (FB102) with early promise in vitiligo and celiac disease, aiming to create a second growth engine before Vyvgart’s peak.
Market read
This is a headline M&A catalyst with explicit deal economics and a stated close window, creating tradable spread dynamics for both ARGX and FBRX ahead of Q3 2026.
What to watch
The article does not detail financing structure, regulatory pathway, or specific closing conditions; those items can materially change deal probability and therefore the pre-close trading spread.
Background
argenx is described as heavily dependent on Vyvgart, with expectations that its growth peaks in the early 2030s, motivating a pipeline expansion via FB102.
Ticker impact
argenx agreed to buy Forte Biosciences for about $2.2B cash at $77/share, adding FB102 to its immunology pipeline.
Near-term volatility likely around deal-spread, regulatory/closing-condition headlines, and any new FB102 readouts; direction depends on financing and diligence updates.
The article provides deal economics, pipeline rationale, and notes ARGX shares fell on announcement before paring losses, implying mixed market interpretation rather than a clean rerating.
Forte Biosciences agreed to be acquired by argenx for about $2.2B cash, paying $77/share, roughly a 40% premium.
Price should track the offer premium and deal-completion probability, with pre-close risk premium compressing if conditions progress.
The article states the offer price and premium, highlights premarket trading near $77.86, and flags remaining closing conditions into Q3 2026.
Market effects
Signals continued consolidation in autoimmune biotech and willingness to pay for early-stage immunology assets, potentially influencing deal expectations for similar pipeline-stage companies.
Limited direct regional impact beyond sentiment for US biotech M&A, with Forte described as a small Dallas-based biotech.
Moderate, as the transaction is US-listed and focused on immunology drug development rather than a global macro shock.
Counterpoint
The buyer’s modest initial drop suggests the market may view FB102 as too early-stage for the $2.2B price, making the acquisition a valuation risk rather than a clear accretive growth step.
Key entities
- acquirerargenx SE
Agreed to buy Forte Biosciences for about $2.2B cash at $77/share, adding FB102 to its immunology pipeline.
- targetForte Biosciences, Inc.
Agreed to be acquired by argenx; deal price is about $77/share with roughly a 40% premium and expected Q3 2026 close.
- drug_candidateFB102
Experimental first-in-class anti-CD122 antibody with early promise in vitiligo and celiac disease, per analysts cited in the article.
